274 related articles for article (PubMed ID: 25301086)
1. Metabolic syndrome and outcomes following early-stage breast cancer.
Calip GS; Malone KE; Gralow JR; Stergachis A; Hubbard RA; Boudreau DM
Breast Cancer Res Treat; 2014 Nov; 148(2):363-77. PubMed ID: 25301086
[TBL] [Abstract][Full Text] [Related]
2. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.
Boudreau DM; Yu O; Chubak J; Wirtz HS; Bowles EJ; Fujii M; Buist DS
Breast Cancer Res Treat; 2014 Apr; 144(2):405-16. PubMed ID: 24557337
[TBL] [Abstract][Full Text] [Related]
4. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women.
Motoki AH; Buttros DAB; Gaspar AL; Almeida-Filho BS; Carvalho-Pessoa E; Vespoli HDL; Nahas-Neto J; Nahas EAP
Clin Breast Cancer; 2022 Feb; 22(2):e253-e261. PubMed ID: 34465534
[TBL] [Abstract][Full Text] [Related]
5. Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.
Chen L; Chubak J; Boudreau DM; Barlow WE; Weiss NS; Li CI
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1603-1610. PubMed ID: 28807926
[No Abstract] [Full Text] [Related]
6. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.
Zanardi E; Di Meglio A; Boccardo C; Zinoli L; Salvi S; Rubagotti A
Oncol Res Treat; 2020; 43(7-8):362-371. PubMed ID: 32512573
[TBL] [Abstract][Full Text] [Related]
7. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Frequent antibiotic use and second breast cancer events.
Wirtz HS; Buist DS; Gralow JR; Barlow WE; Gray S; Chubak J; Yu O; Bowles EJ; Fujii M; Boudreau DM
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1588-99. PubMed ID: 23833124
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
[TBL] [Abstract][Full Text] [Related]
11. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
12. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
13. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
15. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
16. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
Oudanonh T; Nabi H; Ennour-Idrissi K; Lemieux J; Diorio C
Int J Cancer; 2020 May; 146(10):2736-2745. PubMed ID: 31403177
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
Mukhtar RA; Moore AP; Tandon VJ; Nseyo O; Twomey P; Adisa CA; Eleweke N; Au A; Baehner FL; Moore DH; McGrath MS; Olopade OI; Gray JW; Campbell MJ; Esserman LJ
Ann Surg Oncol; 2012 Nov; 19(12):3979-86. PubMed ID: 22622474
[TBL] [Abstract][Full Text] [Related]
20. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
